GleamWall
中文EN

CYTK CYTOKINETICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%

Returns

ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$47.56M$28.62M$19.36M$17.75M$1.94M$66.77M$1.58M$16.93M
R&D expense$99.28M$97.81M$95.53M$104.40M$97.30M$110.14M$98.26M$93.63M
SG&A expense$113.14M$104.40M$104.90M$91.72M$69.46M$65.72M$57.37M$62.34M
Operating income-$167.09M-$179.17M-$183.62M-$178.37M-$166.75M-$111.51M-$155.63M-$139.04M
Interest expense———$14.27M$11.35M$11.08M—$8.94M
Net income-$190.07M-$198.76M-$206.03M-$183.03M-$306.18M-$134.37M-$161.38M-$150.02M
EBITDA-$163.44M-$175.54M-$180.24M-$175.50M-$164.08M-$109.22M-$153.33M-$136.66M
EPS (basic)-1.37-1.50-1.67—-2.55-1.12-1.36—
EPS (diluted)-1.37-1.50-1.67—-2.55-1.12-1.36—
Weighted avg. shares (diluted)139,045132,086123,273—119,982119,457118,496—
Balance sheet
Cash & equivalents$203.43M$255.27M$129.84M$122.52M$225.47M$74.94M$73.68M$94.86M
Short-term investments$926.59M$910.41M$688.71M$759.70M$737.07M$783.20M$864.54M$981.16M
Receivables$33.89M$24.43M$6.83M$17.76M$1.81M$8.41M$2.01M$16.65M
Inventory$807,000$380,000$154,000$0————
Current assets$1.19B$1.21B$839.47M$916.98M$977.35M$886.54M$956.05M$1.11B
PP&E, net$76.12M$78.92M$82.44M$79.19M$76.00M$70.22M$67.17M$65.81M
Total assets$1.82B$1.92B$1.27B$1.42B$1.44B$1.23B$1.26B$1.40B
Current liabilities$353.42M$181.43M$199.19M$202.45M$142.14M$131.06M$159.73M$179.67M
Short-term debt$174.40M$27.36M$44.81M$41.18M$17.28M$14.40M$12.96M$11.52M
Long-term debt$244.33M$248.20M$247.21M$246.38M$158.75M$159.06M$92.03M$93.23M
Total debt$418.73M$275.56M$292.02M$287.56M$176.03M$173.46M$104.98M$104.75M
Total liabilities$2.15B$2.10B$2.10B$2.08B$1.96B$1.59B$1.53B$1.54B
Shareholders' equity-$321.17M-$173.49M-$826.57M-$659.62M-$521.12M-$368.72M-$266.41M-$135.37M
Net debt$215.30M$20.29M$162.17M$165.05M-$49.44M$98.52M$31.30M$9.89M
Shares outstanding———122.94M———118.21M
Cash flow statement
Operating cash flow-$124.02M-$159.84M-$145.46M-$142.65M-$107.50M-$128.24M-$131.62M-$65.57M
Capital expenditure$700,000$4.33M$5.93M$5.64M$9.35M$4.14M$5.66M$1.29M
Free cash flow-$124.72M-$164.17M-$151.39M-$148.29M-$116.86M-$132.38M-$137.28M-$66.86M
Investing cash flow$67.93M-$507.00M$145.49M-$71.19M-$70.98M$52.88M$105.96M$110.86M
Financing cash flow$4.80M$792.86M$7.77M$110.70M$330.47M$78.53M$4.75M$2.38M
Depreciation & amortization$3.65M$3.63M$3.38M$2.86M$2.68M$2.29M$2.30M$2.38M
Stock-based compensation$34.72M$35.71M$30.39M$30.51M$30.70M$27.54M$23.55M$26.25M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.